RD162 is a second-generation androgen receptor (AR) antagonist. It inhibits binding of ¹⁸F-FDHT to AR in human prostate cancer cells with an IC₅₀ value of 30.9 nM.¹ RD162 completely suppresses VCaP cell proliferation at 1 µM and induces apoptosis of VCaP cells at 10 µM. RD162 is bioavailable and reduces LNCaP/AR tumor growth in castrated male mice at a daily oral dose of 10 mg/kg.¹

≥98%

Store at -20℃

1.Tran, C.,Ouk, S.,Clegg, N.J., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324(5928), 787-790 (2009).